Recruitment

Recruitment Status
Completed

Exclusion Criterias

History of malignancy within the past 5 years
Active infection or inflammation in any eye
Uncontrolled hypertension
...
History of malignancy within the past 5 years
Active infection or inflammation in any eye
Uncontrolled hypertension
Panretinal or focal/drid laser photocoagulation within the last 3 and 4 months respectively
use of corticosteroids for at least 30 days in the last 6 months
treatment with anti-angiogenic drugs in any eye within last 3 months

Summary

Conditions
Central Retinal Vein Occlusion
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Outcomes Assessor)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Exclusion Criterias

History of malignancy within the past 5 years
Active infection or inflammation in any eye
Uncontrolled hypertension
...
History of malignancy within the past 5 years
Active infection or inflammation in any eye
Uncontrolled hypertension
Panretinal or focal/drid laser photocoagulation within the last 3 and 4 months respectively
use of corticosteroids for at least 30 days in the last 6 months
treatment with anti-angiogenic drugs in any eye within last 3 months

Locations

Taipei
Harbin, Heilongjiang, 150001
Wenzhou, Zhejiang, 325027
Beijing, Beijing, 100191
Nantong, Jiangsu, 226000
...
Taipei
Harbin, Heilongjiang, 150001
Wenzhou, Zhejiang, 325027
Beijing, Beijing, 100191
Nantong, Jiangsu, 226000
Wuhan, Hubei, 430070
Jakarta, 10430
Qingdao, Shandong, 266011
Chengdu, Sichuan, 610041
Chongqing, 400038
Tianjin, Tianjin, 300020
Manila, Metro Manila, 1000
Lin-Kou, 33305
Hongkong
Ho Chi Minh City, 70000
Bandung, Jawa Barat, 40117
Bhubaneswar, Orissa, 751 024
Changsha, Hunan, 410011
Beijing, 100176
Shanghai, 200080
Tianjin, Tianjin, 300070
Ahmedabad, Gujarat, 380 016
Beijing, 100730
Shantou, Guangdong, 515041
San Juan City, 1500
Nanchang, Jiangxi, 330006
Beijing, Beijing, 100730
Nanjing, Jiangsu, 210006
Guangzhou, Guangdong, 510060
Shanghai, 200092
Hanoi, 10000
Chongqing, Chongqing, 400042
Nanjing, Jiangsu, 210029
Beijing, 100034

Tracking Information

NCT #
NCT01976312
Collaborators
Not Provided
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals